Bibliografía
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Cancer J Clin 2005 ; 55 : 74-108.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 ; 340 : 745-50.
3. Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL, Wong J. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001 ; 19 : 3037-44.
4. Francavilla A, Polimeno L, DiLeo A, et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 1989 ; 9 : 614-20.
5. Claviere C, Bronowicki JP, Hudziak H, Bigard MA, Gaucher P. Role of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma. Gastroenterol Clin Biol 1998 ; 2 : 73-86.
6. Villa E, Grottola A, Colantoni A, De Maria N, Buttafoco P, Ferretti I, Manenti F Hepatocellular carcinoma: role of estrogen receptors in the liver. Ann N Y Acad Sci 2002 ; 963: 37-45.
7. Eagon PK, Elm MS, Epley MJ, Shinozuka H, Rao KN. Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gastroenterology 1996 ; 110 : 1199-207.
8. Nagasue N, Yu L, Yukaya H, Kohno H, Nakamura T. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg. 1995; 82 : 542-7.
9. Nagasue N, Kohno H, Yamanoi A, Kimoto T, Chang YC, Nakamura T. Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors. Cancer 1991 ; 67 : 2501-5.
10. Jonas S, Bechstein WO, Heinze T, et al. Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. Surgery 1997 ; 121: 456-61.
11. Ng IO, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol 1997 ; 92 : 1355-8.
12. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005 ; 23: 4338-46.
13. Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 1990 ; 126 : 3223-31.
14. Simard J, de Launoit Y, Haagensen DE, Labrie F. Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. Endocrinology 1992 ; 130 : 1115-21.
15. Sugimoto K, Simard J, Haagensen DE, Labrie F. Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J Steroid Biochem Mol Biol 1994 ; 51 : 167-74.
16. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002 ; 2 : 485-95.
17. Utsunomiya T, Ogawa K, Yoshinaga K, et al. Clinicopathologic and prognostic values of apolipoprotein D alterations in hepatocellular carcinoma. Int J Cancer 2005 ; 116 :105-9.
18. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005 ; 23: 8093-108.
19. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999 ; 19 : 329-38.
20. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 ; 60 : 646-9.
21. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002 ; 117 : 723-8.
22. Boix L, Bruix J, Castells A, et al. Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? J Hepatol 1993 ; 17 : 187-91.
23. Boix L, Castells A, Bruix J, et al. Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 1995 ; 22 : 616-22.
24. Farinati F, Salvagnini M, de Maria N, et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990 ; 11: 297-301.
25. Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol, 1994 ; 20 : 702-6.
26. Elba S, Buongiorno GP, Caruso ML, Noviello MR, Manghisi OG. Main characteristics of hepatocellular carcinoma and cirrhosis and therapeutic approaches. Curr Pharm Des 2002 ; 8 : 1007-11
27. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen : a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995 ; 109 : 917-22.
28. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995 ; 21 : 1535-42.
29. CLIP Group . Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998 ; 352 : 17-20.
30. Riestra S, Rodriguez M, Delgado M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998 ; 26 : 200-3.
31. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000 ; 95 : 218-22.
32. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002 ; 36 : 1221-6.
33. Grazi GL, Cescon M, Ravaioli M, et al. Liver resection for hepatocellular carcinoma in cirrhotics and non-cirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 2003 ;17 (Suppl 2) :119-29.
34. Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006 ; 12 : 4614-8.
35. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer 2006 ; 106 : 2576-82.
36. Groupe d´Etude et de Traitement du Carcinome Hepatocellulaire. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004 ; 40 : 1361-9.
37. López-Boado YS, Tolivia J, López-Otín C. Apolipoprotein D gene induction by retinoic acid is concomitant with growth arrest and cell differentiation in human breast cancer cells. J Biol Chem 1994 ; 269 : 26871-8.
38. López-Boado YS, Diez-Itza I, Tolivia J, López-Otín C. Glucocorticoids and androgens up-regulate the Zn-alpha 2-glycoprotein messenger RNA in human breast cancer cells. Breast Cancer Res Treat 1994 ; 29 : 247-58.
39. P'eng FK, Lui WY, Chang TJ, et al. Glucocorticoid receptors in hepatocellular carcinoma and adjacent liver tissue. Cancer 1988 ; 62 : 2134-8.
40. Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M. Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin Cancer Res 2003 ; 9 : 3679-83.
41. Clerici C, Castellani D, Russo G, et al. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. Anticancer Res 2004 ; 24 : 1255-60.
|